Single-pulse administration of rhG-colony-stimulating factor (CSF) t o neonatal rats was previously demonstrated t o induce peripheral neutrophilia and modulate bone marrow (BM) neutrophil storage and proliferative pools (NSP + NPP). In this study, we investigated the prolonged effects of 7 days of rhG-CSF therapy (5 pg/kg/per day). Sprague-Dawley newborn rats (524 hours) were injected intraperitoneally (IP) (daily for 7 days) with rhG-CSF or phosphate-buffered saline/ human serum albumin (PBS/ HSA). RhG-CSF induced a significant early and late peripheral neutrophilia: 6,905 ? 1,625 (day 1 ) and 9,223 ? 51 5 pL (day 7) v 1,275 ? 9O/pL ( P I .OW1 1. In addition, 7 days of rhG-CSF resulted in a significant increase in the BM NSP:
Single-pulse administration of rhG-colony-stimulating factor (CSF) t o neonatal rats was previously demonstrated t o induce peripheral neutrophilia and modulate bone marrow (BM) neutrophil storage and proliferative pools (NSP + NPP). In this study, we investigated the prolonged effects of 7 days of rhG-CSF therapy (5 pg/kg/per day). Sprague-Dawley newborn rats (524 hours) were injected intraperitoneally (IP) (daily for 7 days) with rhG-CSF or phosphate-buffered saline/ human serum albumin (PBS/ HSA). RhG-CSF induced a significant early and late peripheral neutrophilia: 6,905 ? 1,625 (day 1 ) and 9,223 ? 51 5 pL (day 7) v 1,275 ? 9O/pL ( P I .OW1 1. In addition, 7 days of rhG-CSF resulted in a significant increase in the BM NSP:
3.247 ? 19O/pL v 1,677 ? 339IpL (P 5 .001). There was, however, no depletion or significant change in the BM NPP. Seven days of rhG-CSF also induced a mild increase in BM CFU-GM colony formation ( P I .01). There was, however,
IGNIFICANT developmental immaturities in neonatal
S host defense predisposes the newborn to a high incidence and mortality rate during overwhelming bacterial infection.' Profound deficiencies in neonatal myelopoiesis and qualitative defects in mature phagocytic effector cell function highlight two of the most important immunologic variables associated with this immaturity in neonatal host defense.'.' In neonatal rats, Christensen et al.3-5 demonstrated reduced BM myeloid progenitor cells, an usually high myeloid progenitor proliferative rate, decreased neutrophil storage pools (NSP) [polymorphonuclear leukocytes (PMN) + band + metamyelocytes], and an increased propensity to develop significant neutropenia during overwhelming bacterial sepsis. In addition, neonatal mature neutrophils have reduced in vitro physiologic function, especially with respect to deformability, chemotaxis, C3bi receptor expression, phagocytosis, and bacterial killing. ' Myelopoiesis, egress of mature granulocytes from the bone marrow (BM), and neutrophil physiologic function all appear to be dependent in part on the presence and action of o 1990 by The American Society of Hematology.
0006-4971/90/7609-0013$3.00/0 no significant change in liver/spleen CFU-GM colonies or in the CFU-GM proliferative rate in either the BM or liver/ spleen cultures. Finally, 7 days of prophylactic rhG-CSF therapy resulted in a synergistic response with antibiotic therapy and significantly modulated the mortality rate during experimental group B streptococcal sepsis (GBS)
(1 00% v 50%) (GvsC) ( P I .001). Pulse rhG-CSF administered at 6 hours or 18 hours after GBS inoculation, however, failed to act synergistically with antibiotics t o improve survival or prevent peripheral neutropenia. This study suggests that 7 days of prophylactic rhG-CSF therapy induces peripheral neutrophilia, myeloid maturation, increases neutrophil BM reserves and also may provide immunologic enhancement of neonatal host defense during experimental GBS in term neonatal rats. hematopoietic colony-stimulating factors (CSF).6 Granulocyte colony-stimulating factor (G-CSF), a myeloid lineagespecific CSF, has been purified to homogeneity from the human bladder carcinoma cell line 5637 and has recently been cloned and recombinantly expressed in Escherichia Recently, human G-CSF, which has a 70% homology with murine G-CSF," has been demonstrated to induce peripheral neutrophilia, stimulate BM myeloid progenitor proliferation and enhance mature granulocyte effector physiologic function.'.' '- I5 We previously demonstrated that single-pulse administration of rhG-CSF to 1-day-old neonatal rats results in a significant increase in peripheral neutrophilia and myeloid proliferative pools (NPP) (blasts + promyelocytes + myelocytes).6.'6 In addition, we also recently reported that single-pulse administration, given either prophylactically or simultaneously with antibiotics during experimental group B streptococcal infection in term neonatal rats, significantly reduces the mortality rate as compared with antibiotic therapy alone." In the present study, we investigated the effect of prolonged administration (7 days) of rhG-CSF in neonatal rats and its subsequent modulation of myelopoiesis and experimental GBS.
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Fisher (Bethesda, MD). The organism was isolated from an infected neonate and serotyped by the precipitin method using rabbit antisera. The organism was grown in Todd-Hewitt broth (THB) BBL Microbiology Systems, Cockeysville, Maryland, to logarithmic phase and then aliquoted and stored at -7OOC until use. Aliquots were thawed and allowed to grow to maximum phase growth in fresh THB. Organisms were then sedimented by centrifugation and washed three times in sterile PBS. Concentration of bacteria was standardized by its optical density at 620 nm, and a suspension of 3 x lo6 organisms per g body weight per 0.100 mL was prepared for injection.
Litters of albino Sprague-Dawley neonatal rats (Bantin-Kingman Laboratories, Fremont, CA) 524 hours (6 to 8 g) were used during this study. Mothers of the litters were received 1 week before delivery and were housed at the vivarium at the University of California Irvine Medical Center. They were maintained at constant room temperature, with water and rodent feed (Purina Chow) ad libitum. Approval for this study was granted by the University Animal Use Committee. Before the neonatal rats were inoculated, the site of injection was washed with Betadine solution (povidone-iodine, lo%, Purdue Frederick, Norwalk, CT). Daily (7 days) IP injections of G-CSF were accomplished with a sterile tuberculin syringe fitted with a 27.5-gauge needle. Antibiotics were administered intramuscularly (IM) in the hind leg. GBS was injected subcutaneously (SC) in the tail region of the animal with a sterile tuberculin syringe.
Quantifcation of circulating, proliferative. and storage pools. Blood samples were obtained daily by nicking the jugular vein with a sterile scalpel, and 10 p L free-flowing blood was collected. Samples were electronically counted (Serano-Baker Diagnostics, Allentown, PA), blood smears were prepared and stained with Wright's stain, and a 100 to 200 cell differential was performed. Absolute neutrophil counts were determined by multiplication of the nucleated cell count by the percentage of neutrophils in the differentials. BM NSP + NPP were determined on day 8 by the method of Christensen et al. 5 Neonatal femurs were aseptically removed, and the contents were flushed into a known quantity of Hanks' balanced salt solution (HBSS, GIBCO, Grand Island, NY). Livers and spleens were also removed on day 8 in a similar manner and finely minced in a known quantity of HBSS. Electronic cell counts were performed on the BM, and a 500-cell differential count was obtained on Wright's-stained cytospin preparations.
Proliferative rates of CFU-GM were evaluated by the thymidine suicide method of Christensen et aL5 BM and combined liver and spleen cells from neonatal rats were placed into each of two 50" centrifuge tubes. To the first aliquot was added 0.34 pug nonradioactive thymidine in a 0.1" vol. The other aliquots received 0.34 pg methyl-'H-thymidine containing 0.1 mCi (specific activity, 75 Ci/mmol, ICN Radiochemicals, Irvine, CA). The tubes were incubated for 20 minutes at 37OC while being agitated every 5 minutes. Thymidine uptake was halted by adding 30 mL of ice-cold a-minimum essential medium (a-MEM) with 5% fetal calf serum (FCS) and 100 pg/mL nonradioactive thymidine. The cell suspensions were then centrifuged and washed twice with the a-MEM/FCS/thymidine media. Cells were then added in the same 1 .I% methylcellulose/a-MEM described above. Colonies were allowed to develop for 14 days in a 5% CO, incubator at 37OC, and thymidine suicide rate was determined by subtracting the average number of colonies formed per plate by cells exposed to 3H-thymidine from the average number of colonies per plate formed by cells exposed to nonradioactive thymidine divided by the average colonies per plate from cells exposed to nonradioactive thymidine.
The 90% lethal dose (LD-90) at 48 to 72 hours after GBS inoculation was determined by injecting neonatal rats as mg/kg per day, and gentamicin (Elkins-Sinn, Cherry Hill, NJ), a total of 6.5 mg/kg per day IM divided in two doses starting 24 hours after infection with GBS; and (d) 7 days PBS/.025% HSA and similar antibiotic therapy. In addition, 1-day-old newborn rats were inoculated with GBS and treated with combinations of rhG-CSF given at either 18 hours after GBS inoculation or at 6 hours (every 12 hours) after GBS and treated with or without additional antibiotics 24 hours after GBS. Mortality and morbidity were monitored throughout the sepsis studies.
BM and liver/spleen cells were collected as described above. Cells were then suspended in a-MEM (GIBCO) with 1 .l% methylcellulose (Terry Fox Laboratories, Vancouver, BC, Canada), 30% vol/vol FCS (Hyclone Laboratories, Logan, UT), 10% bovine serum albumin (BSA) (Sigma) 14.3 x lo-' mol/L mercaptoethanol, 0.01% vol/vol murine spleen cell conditioned medium pokeweed mitogen (PWM) SCCM, (Terry Fox Laboratories), and erythropoietin 1 U/mL (Amgen). Penicillin 100,000 U/L and streptomycin 100 mg/L (P/S) were also added. Cell suspensions were plated in triplicate in 10 x 35-mm tissue culture dishes (Nunc, Denmark) and incubated at 5% C02, 37OC, in a high-humidity atmosphere. Cultures were evaluated at 14 days. Aggregates of more than 50 cells were considered "colonies." Colonies were plucked at random, placed on a slide and stained, and specific lineage was confirmed. Results are reported total cells per marrow and total cells per liver/spleen suspension.
All results are expressed as mean values plus or minus SEM of 8 to 15 animals, or three to five replicates of blood, BM, or liver/spleen samples. The probability of significant differences when two treated groups were compared was determined with the unpaired Student's t test; and the probability of significant differences when multiple treatments were examined was determined by analysis of variance (ANOVA) followed by StudentNewman-Keds multiple-range tests to define the unique subsets within the study. Statistical analyses were performed with the Biostat I statistical program (Sigma Soft, Placentia, CA) for the IBM personal computer. P values < .05 were considered significant.
RESULTS

CFU-GM colony quantification.
Statistical analysis.
Complete blood counts and differentials were obtained on days 1, 3, 5 , and 7 after IP rhG-CSF administration. Within 1 day of rhG-CSF administration, there was a very significant early peripheral neutrophilia (ANC): (6,905 + 1,625/ pL) versus (1,278 9O/pL) (G v C) (P < .004) (Fig 1) . A continuous and prolonged neutrophilia occurred throughout the 7 days of G-CSF administration. On day 7, the ANC was still significantly higher than controls and significantly higher than after the first day of G-CSF therapy: 9,223 + 515 v 1,210 11O/pL (P < .0002): day 7, GvsC (Fig 1) and 9,223 + 515 v 6,905 f 1,905/pL) G-CSF: (day 7 v day 1) (P < .01). Neither were there significant differences in the peripheral lymphocyte, monocyte, or eosinophil counts during the 7 days of G-CSF therapy (data not shown).
The BM NSP was determined on day 8 after 7 days of IP G-CSF or IP PBS/O.O25% HSA. The BM NSP was determined by calculating the total number of PMN + bands + metamyelocytes/pL. After seven daily injections of IP rhG- CSF, the NSP was significantly increased in the G-CSFtreated group of animals as compared with the control group ( P < ,001). (Fig 2) . We also calculated the BM N P P as compared with controls: 2,202 k 248 versus 3,192 + 428 (C v G) (P < .01). There was no difference in liver/spleen CFU-GM, however, between G-CSF-treated and nontreated groups: 3,702 * 1,132 versus 4,568 + 1,674 (G v C) ( P = NS). With regard to progenitor proliferative rates, thymidine suicide studies were performed on myeloid progenitor cells from both the BM and liver/spleens from the day 8 BMs after 7 days of therapy. The BM proliferative rates trended to be higher in the G-CSF group but were not statistically significant (59.9% * 9.8% v 53% k 1.6%) (G v C). In addition, a similar increased trend was noted in the liver/spleen myeloid progenitor colonies: 6 1 % L 1 1.4% versus 52% k 12% (G v C).
Morbidity and mortality were evaluated after 7 days of I P rhG-CSF or PBS/O.O25% HSA and inoculation with GBS on day 8. Animals were weighed 72 hours after GBS inoculation. Neonatal rats pretreated with 7 days of IP rhG-CSF + antibiotics after GBS appeared the healthiest and weighed the most as compared with either the group treated with only rhG-CSF or PBS/O.O25%/HSA + antibiotics. Even the animals that received rhG-CSF without antibiotics weighed more than the animals that received PBS/O.O25% HSA and later antibiotic therapy after GBS: PBS/HSA + antibiotics 15 k 0.28 g, rhG-CSF 17.4 2 0.22 g, and rhG-CSF + antibiotics 19.1 k 0.65 g (P 5 .05).
The mortality rate was also influenced by the 7-day pretreatment with rhG-CSF as compared with PBS/O.O25% HSA-treated animals. Forty-eight hours after GBS inoculation, almost 100% of the control animals without subsequent antibiotic treatment were dead. This compared with a 60% death rate in the rhG-CSF-treated group and a 0% and 10% rate in the antibiotic-treated groups with or without rhG-CSF therapy, respectively. At 72 hours after inoculation of GBS, however, there was 0% survival in both the PBS/ 0.025% HSA group and the rhG-CSF group and only 50% survival in the PBS/O.O25% HSA + antibiotics group. The group of animals pretreated with 7 days of rhG-CSF and then inoculated with GBS and subsequently given antibiotics, still had 100% survival, however (rhG-CSF + Ab v PBS/0.025% HSA + Ab) (100% v 50%) (P < .001) (Fig 3) .
To delineate better the mechanism of synergism of rhG-CSF with antibiotics, newborn animals (1 day) were inoculated with GBS and randomized to rhG-CSF a t either 6 hours or 18 hours k antibiotics 24 hours after GBS. Addition of rhG-CSF at 18 hours after GBS did not induce an increase in survival over antibiotics alone (Fig 4) . In addition, neither did administration of rhG-CSF at 6 hours and then every 12 hours thereafter modulate the survival rate v antibiotics alone (Fig 5) . RhG-CSF 18 hours after GBS failed to prevent neutropenia after overwhelming GBS infection; ANC (pL) 6 hours after rhG-CSF treatment: no GBS 
DISCUSSION
At term, neonatal rat BM myeloid progenitor colonies (CFU-GM) are normally reduced to about 25% of adult rat levels and appear to be proliferating at 80% of capacity as compared with only a 25% proliferative rate in adult rats5 In addition, neonatal rat BM NSP are substantially decreased to about 25% of normal adult rat levels. This immaturity in neonatal rat myeloid host defense results in an increased tendency to develop significant peripheral neutropenia during experimental overwhelming bacterial infe~tion.'.~ Moreover, despite the presence of normal numbers of circulating mature effector granulocytes at the time of sepsis, the neonate may be still susceptible to overwhelming bacterial sepsis secondary to qualitative deficiencies within circulating phagocytes.
G-CSF has been reported to induce peripheral neutrophilia in mice,"," to shorten the period of neutropenia in cynomolus monkeys after cyclopho~phamidel~ and busulfan therapy," and to reduce morbidity successfully after BM transplantation. 21 Recently, rhG-CSF was successfully used to shorten the period of neutropenia after multiagent chemotherapy in humans:' induce peripheral neutrophilia in children with congenital agranulocyt~sis,~' and reverse cyclic neutropenia in both children and adults.24 The acute elevation of the peripheral neutrophil count within 48 hours after G-CSF therapy has been attributed to the release of BM NSP reserves, whereas the prolonged (7 to 10 day) increase in peripheral neutrophil counts after daily G-CSF therapy has been suggested to be secondary to the G-CSF stimulatory effects on BM myeloid progenitor cells.
In the present study, we demonstrated that rhG-CSF has similar significant effects on neonatal myelopoiesis. RhG-CSF, when administered for 7 consecutive days to term newborn rats, induced a profound neutrophilia within the first 24 hours and a sustained and increased response for the next 7 days. At the end of 7 days of rhG-CSF therapy, we also noted a significant increase (100%) in the BM NSP. This dramatic increase in the NSP 1 week after G-CSF therapy did not lead to a depletion of early BM myeloid progenitor cells (NPP), however. These findings are consistent with those of Ulich et al,25 who also reported a 100% increase in the NSP and no change in the NPP in adult rats treated with rhG-CSF for 7 consecutive days.
Erdman et aI4 previously observed that the NSP of 1-week-old neonatal rats represented only 50% of normal -Antibiotic Treatment levels in adult animals. This study demonstrates that 7 days of rhG-CSF therapy to term neonatal rats resulted in increasing the NSP by 100% at age 1 week. This doubling of the NSP at age 1 week begins to approach the normal adult rat BM NSP reported by Erdman et al. 4 The present study also showed that neonatal rat bone marrow myeloid progenitor colonies (CFU-GM) increased after 7 days of IP rhG-CSF without, however, any increase in liver/spleen CFU-GM. Christensen et a13 previously demonstrated that 1-weekold neonatal rats possess only about 20% to 25% of normal adult rat CFU-GM colony activity. The lack of response in liver/spleen CFU-GM in this study is consistent with the hypothesis that with increasing age a progressive reduction occurs in CFU-GM colony activity in both liver and spleen after GBS inoculation, there was still 100% survival in the rhG-CSF plus antibiotic-treated group as compared with survival of only 50% in the PBS/HSA plus antibiotic group. In addition, in the present study and as expected, 7 days of rhG-CSF therapy without subsequent antibiotic therapy did not enhance survival during GBS. Most important, however, rhG-CSF delayed onset of death as compared with PBS/ HSA-treated control animals, suggesting that prophylactic rhG-CSF may enhance neonatal host defense by allowing the host more time to mount an immunologic response. We also noted a significant increase in the weight of animals treated with rhG-CSF f antibiotics as compared with their control groups. rhG-CSF administered 18 hours after GBS or 6 hours after GBS (every 12 hours) failed to prevent neutropepools in developing neonatal rats.
Broxmeyer et a126 also failed to document an increase in BM and spleen CFU-GM after pulse administration of rhG-CSF (1 to 2 x lo3 U) to adult mice, but in higher doses of lo4 U, both BM and spleen CFU-GM colony activity increased. Duhrsen et al.27 also noted that 5-day administration of rhG-CSF to adult cancer patients also failed to cause a significant increase in BM CFU-GM activity. In the nia or improve survival with supplemental antibiotic therapy, however. These combined studies suggest that 7 days of rhG-CSF therapy induces a significant peripheral neutrophilia and accumulation of BM NSP reserves. This increase in the BM NSP appears to prevent the NSP depletion that has been previously demonstrated with overwhelming GBS infection. Single or multiple pulses of rhG-CSF given after GBS inoculation, however, fail to sustain the peripheral present study, we also found no increase in the CFU-GM proliferative rate in either BM or liver/spleens after 7 days of IP rhG-CSF. Because the CFU-GM proliferative activity is already much higher in newborn rats as compared with adult animals, it is not surprising to fail to document a significant increase in this age group. These findings are somewhat different from those of Broxmeyer et a1. : 6 who demonstrated an increase in CFU-GM S-phase activity in mouse BM and spleens after high-dose rhG-CSF and pretreatment with lactoferrin.
We also showed that 7 days of rhG-CSF in newborn rats modulates morbidity and mortality associated with overwhelming group B streptococcal sepsis. Seventy-two hours neutrophil count, lead to significant neutropenia, and result in a high mortality rate.
Matsumoto et a128 and Tanaka et a129 also demonstrated the beneficial effects of rhG-CSF in adult cyclophosphamidetreated mice inoculated with Pseudomonas and of rmGM-CSF in cyclophosphamide-treated adult mice also inoculated with Pseudomonas. Recently, Silver et al" also reported significant synergistic activity of rhG-CSF plus gentamicin therapy in mice with Pseudomonas burn-induced sepsis.
The improvement in the mortality rate after 7 days of IP rhG-CSF presumably occurs secondary to stimulation of myeloid maturation; however, an enhancement of mature granulocyte effector function cannot be ruled out. G-CSF 
